company background image
RVPH logo

Reviva Pharmaceuticals Holdings NasdaqCM:RVPH Stock Report

Last Price

US$3.90

Market Cap

US$108.9m

7D

39.3%

1Y

-16.3%

Updated

27 Mar, 2024

Data

Company Financials +

Reviva Pharmaceuticals Holdings, Inc.

NasdaqCM:RVPH Stock Report

Market Cap: US$108.9m

RVPH Stock Overview

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases.

RVPH fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Reviva Pharmaceuticals Holdings, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Reviva Pharmaceuticals Holdings
Historical stock prices
Current Share PriceUS$3.90
52 Week HighUS$9.25
52 Week LowUS$2.67
Beta-0.023
1 Month Change-10.34%
3 Month Change-22.16%
1 Year Change-16.31%
3 Year Change-32.06%
5 Year Change-61.39%
Change since IPO-59.84%

Recent News & Updates

Recent updates

Here's Why Reviva Pharmaceuticals Holdings (NASDAQ:RVPH) Must Use Its Cash Wisely

Aug 24
Here's Why Reviva Pharmaceuticals Holdings (NASDAQ:RVPH) Must Use Its Cash Wisely

We're Keeping An Eye On Reviva Pharmaceuticals Holdings' (NASDAQ:RVPH) Cash Burn Rate

Dec 28
We're Keeping An Eye On Reviva Pharmaceuticals Holdings' (NASDAQ:RVPH) Cash Burn Rate

Reviva Pharmaceuticals drops 9% on $8.5M private placement

Sep 06

We're A Little Worried About Reviva Pharmaceuticals Holdings' (NASDAQ:RVPH) Cash Burn Rate

Aug 24
We're A Little Worried About Reviva Pharmaceuticals Holdings' (NASDAQ:RVPH) Cash Burn Rate

Reviva Pharmaceuticals Q2 GAAP loss per share widens

Aug 15

Reviva reports positive brilaroxazine results in Aacute Schizophrenia

Apr 26

Shareholder Returns

RVPHUS PharmaceuticalsUS Market
7D39.3%1.2%0.4%
1Y-16.3%25.8%28.8%

Return vs Industry: RVPH underperformed the US Pharmaceuticals industry which returned 23.9% over the past year.

Return vs Market: RVPH underperformed the US Market which returned 29.5% over the past year.

Price Volatility

Is RVPH's price volatile compared to industry and market?
RVPH volatility
RVPH Average Weekly Movement11.9%
Pharmaceuticals Industry Average Movement9.7%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: RVPH's share price has been volatile over the past 3 months.

Volatility Over Time: RVPH's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201810Laxminarayan Bhathttps://www.revivapharma.com

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company’s lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer’s disease, Parkinson’s disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity.

Reviva Pharmaceuticals Holdings, Inc. Fundamentals Summary

How do Reviva Pharmaceuticals Holdings's earnings and revenue compare to its market cap?
RVPH fundamental statistics
Market capUS$108.88m
Earnings (TTM)-US$37.65m
Revenue (TTM)n/a

0.0x

P/S Ratio

-2.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RVPH income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$37.65m
Earnings-US$37.65m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.35
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio-2.6%

How did RVPH perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.